BioNTech

The new data supports the continued marketing of BioNTech's breast cancer subtyping assay as an alternative to IHC, and suggests added value for the test in assessing Ki-67 specifically.

The two partners hope to start a Phase I combination trial pairing Genentech's anti-PDL1 cancer immunotherapy Tecentriq with vaccines developed using BioNTech's IVAC Mutanome. 

The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.

The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.